Lorabid Dosage
Generic name: loracarbef
Dosage form: Capsule, Suspension
Drug class: Second generation cephalosporins
Medically reviewed by Drugs.com. Last updated on Sep 30, 2024.
Lorabid is administered orally either at least 1 hour prior to eating or at least 2 hours after eating. The recommended dosages, durations of treatment, and applicable patient populations are described in the following chart:
| DOSAGE | Duration | |
| POPULATION/INFECTION | (mg) | (days) |
| ADULTS (13 years and older) | ||
| Lower Respiratory Tract | ||
| Secondary Bacterial Infection of Acute Bronchitis | 200–400 q12h | 7 |
| Acute Bacterial Exacerbation of Chronic Bronchitis | 400 q12h | 7 |
| Pneumonia | 400 q12h | 14 |
| Upper Respiratory Tract | ||
| Pharyngitis/Tonsillitis | 200 q12h | 10a |
| Sinusitis | 400 q12h | 10 |
| (SeeCLINICAL STUDIESand INDICATIONS AND USAGE for further information.) | ||
| Skin and Skin Structure | ||
| Uncomplicated Skin and Skin Structure Infections | 200 q12h | 7 |
| Urinary Tract | ||
| Uncomplicated cystitis | 200 q24h | 7 |
| (SeeCLINICAL STUDIESandINDICATIONS AND USAGE for further information.) | ||
| Uncomplicated pyelonephritis | 400 q12h | 14 |
| PEDIATRIC PATIENTS (6 months to 12 years) | ||
| Upper Respiratory Tract | ||
| Acute Otitis Mediab | 30 mg/kg/day in | 10 |
| divided doses q12h | ||
| (See CLINICAL STUDIESandINDICATIONS AND USAGE for further information.) | ||
| Acute maxillary sinusitis | 30 mg/kg/day in | 10 |
| divided doses q12h | ||
| (See CLINICAL STUDIESandINDICATIONS AND USAGE for further information.) | ||
| Pharyngitis/Tonsillitis | 15 mg/kg/day in | 10a |
| divided doses q12h | ||
| Skin and Skin Structure | ||
| Impetigo | 15 mg/kg/day in | 7 |
| divided doses q12h | ||
| a In the treatment of infections due to S. pyogenes, Lorabid should be administered for at least 10 days. | ||
|
b Otitis media should be treated with the suspension. Clinical studies of otitis media were conducted with the suspension formulation only. The suspension is more rapidly absorbed than the capsules, resulting in higher peak plasma concentrations when administered at the same dose. Therefore, the capsule should not be substituted for the suspension in the treatment of otitis media (seeCLINICAL PHARMACOLOGY). |
||
| 100 mg/5 mL Suspension | 200 mg/5 mL Suspension | ||||
| Weight | Dose given twice daily | Dose given twice daily | |||
| lb | kg | mL | tsp | mL | tsp |
| 15 | 7 | 2.6 | 0.5 | — | — |
| 29 | 13 | 4.9 | 1.0 | 2.5 | 0.5 |
| 44 | 20 | 7.5 | 1.5 | 3.8 | 0.75 |
| 57 | 26 | 9.8 | 2.0 | 4.9 | 1.0 |
| 100 mg/5 mL Suspension | 200 mg/5 mL Suspension | ||||
| Weight | Dose given twice daily | Dose given twice daily | |||
| lb | kg | mL | tsp | mL | tsp |
| 15 | 7 | 5.2 | 1.0 | 2.6 | 0.5 |
| 29 | 13 | 9.8 | 2.0 | 4.9 | 1.0 |
| 44 | 20 | — | — | 7.5 | 1.5 |
| 57 | 26 | — | — | 9.8 | 2.0 |
Renal Impairment: Lorabid may be administered to patients with impaired renal function. The usual dose and schedule may be employed in patients with creatinine clearance levels of 50 mL/min or greater. Patients with creatinine clearance between 10 and 49 mL/min may be given half of the recommended dose at the usual dosage interval, or the normal recommended dose at twice the usual dosage interval. Patients with creatinine clearance levels less than 10 mL/min may be treated with the recommended dose given every 3 to 5 days; patients on hemodialysis should receive another dose following dialysis.
When only the serum creatinine is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance (CLcr, mL/min). The equation assumes the patient's renal function is stable.
| (weight in kg) x (140 - age) | |
| Males = | (72) x serum creatinine (mg/100 mL) |
| Females = | (0.85) x (above value) |
| Bottle Size | Reconstitution Direction |
| 100 mL | Invert the bottle and tap to loosen powder. Add 60 mL of water in 2 portions to the dry mixture in the bottle. |
| Shake well after each addition. |
After mixing, the suspension may be kept at room temperature, 15–30°C (59–86°F), for 14 days without significant loss of potency. Keep tightly closed. Discard unused portion after 14 days.
More about Lorabid (loracarbef)
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- During pregnancy
- Drug class: second generation cephalosporins
- Breastfeeding
Patient resources
Other brands
Professional resources
Related treatment guides
See also:
Amoxicillin/clavulanate
Amoxicillin and clavulanate potassium is a combination antibiotic used to treat bacterial ...
Nitrofurantoin
Nitrofurantoin is an antibiotic used to treat urinary tract infections. Learn about side effects ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Guaifenesin
Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat. Includes ...
Cefdinir
Cefdinir systemic is used for bacterial infection, bronchitis, middle ear infections, pneumonia ...
Levofloxacin
Levofloxacin is a fluoroquinolone antibiotic used to treat serious bacterial infections and prevent ...
Augmentin
Augmentin is a prescription antibiotic combining amoxicillin and clavulanate to treat bacterial ...
Ceftriaxone
Ceftriaxone systemic is used for bacteremia, bacterial endocarditis prevention, bacterial ...
Clindamycin
Clindamycin (Cleocin) is used to treat serious infections caused by bacteria. Includes clindamycin ...
Cephalexin
Cephalexin is a cephalosporin antibiotic used to treat bacterial infections like respiratory, skin ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
